Aref Al‐Kali

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Peter L. Greenberg, Richard M. Stone, Aref Al‐Kali et al. · Journal of the National Comprehensive Cancer Network · 2016 · 293 citations

Hematological Malignancy, Oncology, Diagnostic Classification +14

A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors

Fei Yan, Aref Al‐Kali, Zijie Zhang et al. · Cell Research · 2018 · 251 citations · Full text

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

Ayalew Tefferi, Terra L. Lasho, Thitina Jimma et al. · Mayo Clinic Proceedings · 2012 · 240 citations · Full text

Hematological Malignancy, Mayo Clinic Experience, Hematology +4

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

Animesh Pardanani, Rebecca R. Laborde, Terra L. Lasho et al. · Leukemia · 2013 · 229 citations · Full text

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

Mrinal M. Patnaik, Eric Padron, Rebecca R. Laborde et al. · Leukemia · 2013 · 215 citations

Hematological Malignancy, Oncology, Engineering +12